List of Excipients in Branded Drug XOPENEX HFA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Lupin Pharmaceuticals Inc	XOPENEX HFA	levalbuterol tartrate	27437-056	ALCOHOL	1969-12-31
Lupin Pharmaceuticals Inc	XOPENEX HFA	levalbuterol tartrate	27437-056	NORFLURANE	1969-12-31
Lupin Pharmaceuticals Inc	XOPENEX HFA	levalbuterol tartrate	27437-056	OLEIC ACID	1969-12-31
Physicians Total Care Inc	XOPENEX HFA	levalbuterol tartrate	54868-5689	ALCOHOL	1969-12-31

Xopenex HFA Excipient Strategy and Commercial Opportunities

Last updated: August 2, 2026

Xopenex HFA is a levalbuterol tartrate pressurized metered-dose inhaler containing ethanol and HFA-134a as its principal excipients. The formulation is commercially mature, and its strongest opportunities are generic substitution, device-led differentiation, lower-global-warming-potential propellant conversion, and expansion into markets where levalbuterol remains differentiated from racemic albuterol. Original formulation and method-of-use exclusivity has largely expired, leaving device performance, regulatory execution, manufacturing scale, and supply reliability as the main barriers.

What is the Xopenex HFA formulation?

Xopenex HFA delivers levalbuterol tartrate through a pressurized metered-dose inhaler. Levalbuterol is the R-enantiomer of albuterol and is used for treatment or prevention of bronchospasm in patients with reversible obstructive airway disease.

Attribute	Xopenex HFA
Active ingredient	Levalbuterol tartrate
Delivered strength	45 mcg levalbuterol per actuation
Equivalent levalbuterol base	Approximately 41 mcg per actuation
Dosage form	Pressurized metered-dose inhaler
Canister fill	15 g
Labeled actuations	200 actuations
Propellant	1,1,1,2-tetrafluoroethane, HFA-134a
Co-solvent	Ethanol
Preservative	None identified in the FDA label
Surfactant	None identified in the FDA label
Original NDA	NDA 021730
FDA dosage-form approval	2005
Originator company	Sepracor, later acquired by Sunovion Pharmaceuticals
Current therapeutic class	Short-acting beta2-adrenergic agonist

The FDA prescribing information identifies ethanol and HFA-134a as inactive ingredients. The product does not use the chlorofluorocarbon propellants found in older inhalers.[1]

Which excipients protect Xopenex HFA performance?

Why does Xopenex HFA use ethanol?

Ethanol is the formulation’s principal co-solvent. It helps dissolve or disperse levalbuterol tartrate within the propellant system and influences several product-performance variables:

• Drug solubility and concentration uniformity
• Valve metering consistency
• Spray plume geometry
• Droplet-size distribution
• Evaporation rate after actuation
• Canister and valve compatibility
• Delivered-dose uniformity over the product shelf life

The ethanol concentration is a critical quality attribute. A higher concentration may improve solubility but can alter plume force, evaporation behavior, taste, throat deposition, and emitted-particle size. A lower concentration can create precipitation, suspension instability, valve-dose variability, or manufacturing difficulties.

For a generic developer, matching the reference product’s ethanol level is not sufficient by itself. The applicant must demonstrate comparable delivered dose, aerodynamic particle-size distribution, spray pattern, plume geometry, priming behavior, tail-off performance, and robustness under temperature and humidity stress.

Why does Xopenex HFA use HFA-134a?

HFA-134a is the propellant that supplies pressure and atomizes the formulation. Its commercial advantages include established pharmaceutical use, broad regulatory precedent, and compatibility with standard aluminum canisters, metering valves, and actuator systems.

Its principal strategic disadvantage is environmental. HFA-134a has a relatively high global-warming potential compared with newer propellant candidates. The product is therefore exposed to long-term pressure for lower-emission inhaler technology, although regulatory treatment of medical aerosols differs from nonmedical uses.

What excipients are not used in Xopenex HFA?

The labeled formulation does not identify oleic acid, lecithin, sorbitan trioleate, or another conventional surfactant. It also does not identify a preservative. This relatively simple formulation reduces the number of excipient-related extractables, leachables, and toxicology variables.

The absence of a surfactant does not eliminate formulation risk. The drug, ethanol, propellant, canister coating, valve elastomers, and actuator must remain compatible throughout storage and repeated use.

How strong is the Xopenex HFA patent estate?

Xopenex HFA’s original patent estate has limited remaining value as a barrier to standard generic entry. Levalbuterol itself is an established small molecule, and the principal commercial protection historically came from composition, inhalation formulation, and method-of-use claims rather than from an active biologic or complex delivery platform.

Protection category	Commercial relevance
Levalbuterol composition patents	Historically important; generally expired or near expiration
HFA inhalation formulation claims	Relevant to early product differentiation; expiration risk is largely historical
Bronchodilator method-of-use claims	Limited current blocking value if expired
Device and valve claims	Potentially relevant where separately patented or proprietary
Manufacturing-process claims	Can protect know-how even when product patents expire
Trade secrets	Important for filling, crimping, dose consistency, and stability control

The FDA Orange Book is the controlling source for listed patents and regulatory exclusivity associated with NDA 021730.[2] Commercial diligence should distinguish between expired listed patents, live device rights, unlisted process patents, and trade secrets. An expired Orange Book patent does not eliminate every possible infringement issue, but it materially reduces the risk of a conventional ANDA challenge.

When does Xopenex HFA lose exclusivity?

Xopenex HFA’s regulatory and patent exclusivity has substantially diminished. The original HFA product was approved in 2005, and the applicable new-drug exclusivity period has expired. Any pediatric exclusivity associated with the product would also have expired years ago.

Exclusivity type	Xopenex HFA position
Five-year new chemical entity exclusivity	Expired
Three-year clinical-investigation exclusivity	Expired
Pediatric exclusivity	Expired, if previously granted
Listed product patents	Historical rights largely expired
Biosimilar exclusivity	Not applicable
Current ANDA pathway	Available for qualifying generic products

Xopenex HFA is not a biologic. Biosimilar risk does not apply. Competition occurs through ANDAs, authorized-generic strategies, alternative levalbuterol inhalers, and racemic albuterol products.

Which companies are challenging Xopenex HFA?

The principal challengers are generic respiratory-product manufacturers capable of developing a drug-device combination product. Publicly reported generic development and approval activity has included companies such as Lupin and other inhalation specialists, although commercial availability varies by market and time.

A generic applicant may proceed through an ANDA with a Paragraph IV certification if an Orange Book patent is listed and considered relevant. If no unexpired blocking patent remains, the applicant may rely on Paragraph III certifications or pursue approval without a Paragraph IV patent dispute.

What Paragraph IV risks exist?

The principal Paragraph IV risk categories are:

1. Formulation claims. A challenger may argue that the reference formulation claims are invalid, unenforceable, or not infringed.
2. Device claims. The applicant may design around the actuator, metering valve, dose counter, or canister configuration.
3. Method-of-use claims. These can be addressed through labeling restrictions or a section viii statement where legally available.
4. Manufacturing claims. These usually create a weaker ANDA barrier if the generic can use a noninfringing process.
5. Drug-device equivalence. FDA approval may remain difficult even after a successful patent challenge if the product cannot match reference-device performance.

The practical litigation risk is lower than for a newly launched inhaled product because the central patents and regulatory exclusivities are mature. The more important risk is technical failure in demonstrating pharmaceutical equivalence and equivalent performance.

What formulation patents protect levalbuterol HFA products?

The most valuable formulation claims generally cover the combination of:

• Levalbuterol or levalbuterol tartrate
• HFA-134a or another hydrofluoroalkane propellant
• Ethanol at a defined concentration range
• A metering valve and actuator
• Delivered-dose consistency
• Fine-particle fraction and aerodynamic performance
• Storage stability and valve compatibility

A new entrant may avoid legacy claims by changing the propellant, ethanol level, suspension or solution state, canister coating, valve design, actuator geometry, or dose strength. Each change creates regulatory comparability work.

A formulation patent can have limited commercial value if the product is easy to design around. A narrow claim requiring a specific ethanol range or valve architecture may protect a particular presentation but not the broader levalbuterol inhaler market.

What commercial opportunities exist for Xopenex HFA competitors?

1. Standard generic levalbuterol HFA

The most direct opportunity is an ANDA product matching the reference inhaler. The value proposition is lower price, payer substitution, and pharmacy-channel access. The main costs are device development, analytical testing, comparative aerodynamic testing, stability studies, and commercial-scale filling.

2. Authorized-generic or supply agreements

A branded manufacturer or contract manufacturer could use an authorized-generic arrangement to preserve channel access after patent expiry. The economics depend on whether the brand owner controls the NDA, manufacturing site, device platform, or distribution contracts.

The public record does not establish a major standalone licensing transaction for Xopenex HFA comparable to large biologic or specialty-drug deals. The relevant corporate event is Sepracor’s acquisition by Dainippon Sumitomo Pharma, which placed Xopenex within the Sunovion portfolio.[3]

3. Lower-emission propellant reformulation

Replacing HFA-134a with a lower-global-warming-potential propellant is the most important long-term formulation opportunity. Potential candidates include HFA-152a and other next-generation inhaler propellants.

A reformulation would require evaluation of:

• Propellant-drug solubility
• Ethanol requirements
• Flammability and handling controls
• Canister pressure
• Valve elastomer compatibility
• Actuator plume characteristics
• Dose uniformity
• Aerosol particle-size distribution
• Toxicology and extractables
• Stability and transport qualification

A new propellant product could obtain differentiated formulation, device, and process patents. It could also command a premium if payers and health systems begin assigning value to lower-emission inhalers.

4. Device differentiation

Xopenex HFA is suitable for device-focused competition. Potential improvements include:

• Integrated dose counters
• Dose-lockout mechanisms
• Improved actuator ergonomics
• Low-residual-volume valves
• Anti-static canister or actuator components
• Priming and cleaning aids
• Packaging that improves adherence and handling

Device claims can create a defensible position even after the active ingredient becomes generic. The commercial return depends on whether FDA and payers recognize the device as clinically or operationally superior.

5. Global market expansion

Levalbuterol HFA opportunities are strongest in markets with:

• Established pressurized inhaler infrastructure
• High use of short-acting bronchodilators
• Reimbursement for branded or differentiated generics
• Limited availability of levalbuterol products
• Local manufacturing incentives

Regulatory filings must account for country-specific requirements for inhaler equivalence, environmental documentation, device registration, and propellant controls. A product that is acceptable under the U.S. ANDA framework may require additional in vitro, clinical, or device evidence elsewhere.

How does Xopenex HFA compare with albuterol HFA?

Factor	Xopenex HFA	Albuterol HFA
Active ingredient	Levalbuterol, R-enantiomer	Racemic albuterol
Therapeutic role	Short-acting bronchodilator	Short-acting bronchodilator
Market size	Smaller	Larger
Generic pressure	High	Very high
Differentiation	Enantiomer-specific positioning	Broad familiarity and lower cost
Excipient platform	Ethanol plus HFA-134a	Varies by product
Premium potential	Historically higher	Generally lower
Clinical switching risk	Formulation and device dependent	Broad substitution base

Albuterol has the larger commercial base and stronger generic penetration. Xopenex HFA retains a narrower opportunity where prescribers, patients, or payers value levalbuterol-specific positioning. That positioning is difficult to sustain without evidence of improved tolerability, adherence, device usability, or formulary economics.

What manufacturing and intellectual-property barriers remain?

The principal barriers are technical rather than molecule-specific.

Manufacturing barriers

• Accurate ethanol and propellant charging
• Uniform drug concentration through the canister
• Reliable crimping and valve insertion
• Control of moisture and contamination
• Consistent actuator geometry
• Canister pressure management
• Long-term valve and elastomer compatibility
• Dose delivery at beginning, middle, and end of canister life

A contract manufacturer with existing HFA filling capacity has a meaningful advantage. Specialized equipment, explosive-atmosphere controls, qualified suppliers, and inhaler testing laboratories increase entry costs.

Intellectual-property barriers

• Device architecture
• Dose-counter integration
• Low-emission propellant systems
• Canister coatings
• Valve materials
• Filling and sealing processes
• Stability-enhancing packaging
• Digital adherence functions

Trade secrets may be more commercially important than expired composition patents. A competitor can legally enter while still facing high development risk if it lacks process knowledge.

What is the FDA and Orange Book status of Xopenex HFA?

Xopenex HFA is an FDA-approved prescription inhalation aerosol under NDA 021730. The FDA label identifies levalbuterol tartrate as the active ingredient and ethanol and HFA-134a as inactive ingredients.[1]

The Orange Book should be used to confirm the current patent listing, reference-listed-drug status, and any applicable exclusivity codes before a filing or launch decision. The product’s mature regulatory history supports an ANDA strategy, but the generic applicant must still satisfy FDA requirements for inhalation-product equivalence, device performance, and labeling.[2,4]

What is the revenue exposure for Xopenex HFA?

Product-level revenue for Xopenex HFA is not generally disclosed separately in public filings. The commercial exposure is therefore best assessed through market structure:

• The product competes with lower-priced albuterol HFA.
• Generic levalbuterol products can reduce price and formulary leverage.
• Prescription volume is sensitive to payer substitution.
• A branded premium requires clinical, device, supply, or environmental differentiation.
• Revenue durability depends on the extent of remaining brand loyalty and contracting.

For an acquirer or licensee, valuation should focus on net sales by channel, gross-to-net deductions, payer tier, generic share, manufacturing cost per canister, and the probability of propellant-transition investment.

What is the strongest commercial strategy for Xopenex HFA?

The highest-probability strategy is a cost-efficient generic or authorized generic using the established ethanol/HFA-134a platform. The highest-upside strategy is a lower-emission levalbuterol inhaler supported by new device and formulation patents.

A conventional branded reformulation without a clear device, environmental, or adherence advantage is less attractive. The active ingredient is mature, the reference product is technically replicable, and albuterol provides a strong low-cost substitute.

Key Takeaways

• Xopenex HFA uses levalbuterol tartrate, ethanol, and HFA-134a.
• Ethanol controls solubility, aerosol formation, valve performance, and dose consistency.
• HFA-134a provides an established platform but creates long-term environmental-transition risk.
• Original composition, formulation, and method-of-use protections have largely expired.
• Biosimilar competition does not apply because levalbuterol is a small molecule.
• Generic entry risk is high, with device equivalence and aerosol performance as the main technical hurdles.
• The best near-term opportunity is a generic or authorized generic.
• The best long-term opportunity is a lower-emission propellant reformulation with device and process protection.
• Standalone Xopenex HFA revenue is not publicly separated in standard corporate reporting.
• Device reliability, manufacturing scale, and supply-chain control are more important than legacy molecule patents.

FAQs

Can ethanol concentration be changed in a generic Xopenex HFA?

Yes, but a change can affect solubility, plume geometry, particle-size distribution, valve performance, and delivered-dose uniformity. The applicant must support the change through the applicable FDA equivalence and CMC package.

Is HFA-152a a practical replacement for HFA-134a in levalbuterol inhalers?

Potentially. HFA-152a has a lower global-warming potential, but it introduces flammability, manufacturing, compatibility, safety, and regulatory-development requirements.

Does Xopenex HFA have biosimilar competition?

No. Levalbuterol is a chemically synthesized small molecule, so competition proceeds through generic-drug pathways rather than the biosimilar pathway.

Can a company launch a levalbuterol dry-powder inhaler against Xopenex HFA?

A dry-powder product would be a different delivery system and may require a separate regulatory strategy. It could avoid some HFA formulation issues but would face new device, usability, dose-delivery, and comparative-performance requirements.

What is the most valuable patent position for a next-generation levalbuterol inhaler?

A broad, enforceable combination of lower-emission propellant formulation, compatible valve and canister materials, consistent aerosol performance, and differentiated device functionality would generally have greater commercial value than a narrow excipient-range claim alone.

References

1. U.S. Food and Drug Administration. (2023). Xopenex HFA (levalbuterol tartrate) inhalation aerosol prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. Dainippon Sumitomo Pharma Co., Ltd. (2010). Acquisition of Sepracor Inc. and Sunovion Pharmaceuticals corporate materials.
4. U.S. Food and Drug Administration. (2023). Product-specific guidance for levalbuterol tartrate inhalation aerosol.